Vivos Therapeutics Announces Q2 2025 Financial Results Release and Conference Call

Vivos Therapeutics will release its Q2 2025 financial results on August 19, 2025, after market close. The company will hold a conference call at 5:00 PM ET to discuss the results and recent milestones. Investors can dial in or access the webcast on Vivos' investor relations website. A replay of the call will be available until September 2, 2025.

Vivos Therapeutics, Inc. (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of treatments for sleep-related breathing disorders, will release its second quarter 2025 financial results after market close on August 19, 2025. The company will hold a conference call at 5:00 PM ET to discuss the results and recent milestones. Investors can dial in or access the webcast on Vivos' investor relations website. A replay of the call will be available until September 2, 2025.

The press release [1] indicates that the company plans to release its Q2 2025 financial results after the market closes on August 19, 2025. The conference call is scheduled at 5:00 PM ET, with a replay available for those unable to attend. Investors can access the webcast on Vivos' website at https://vivos.com/investor-relations.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues. The company's groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children. Vivos' strategic pivot to sleep centers, as evidenced by the acquisition of The Sleep Center of Nevada (SCN), demonstrates a shift in their business model from one reliant on dentists alone to a more integrated approach capturing both diagnostics and treatment revenue [2].

In Q2 2025, Vivos reported revenue of $3.8 million, a decrease from $4.1 million in Q2 2024. Gross profit was $2.1 million, with a 55% margin, compared to 65% in Q2 2024. Operating expenses surged by 52% to $7.0 million, primarily due to SCN acquisition costs. The company ended the quarter with $4.4 million in cash. The acquisition of SCN generated approximately $500,000 in diagnostic sleep testing revenue in just 20 days, translating to a potential annual run rate of $9.1 million [2].

The widening operating loss of $4.9 million, compared to $1.9 million in Q2 2024, warrants monitoring. Management attributes much of the increased expenses to non-recurring professional fees related to the SCN acquisition. The company's cash position of $4.4 million and stockholders' equity of $4.6 million indicate tighter financial resources as they execute this transition.

Vivos' strategic pivot to sleep centers shows early promise despite weaker Q2 numbers. The strong patient demand at SCN locations, with appointments booked weeks out and less than 40% of patients currently being served, suggests substantial untapped revenue potential. The July announcement of a management agreement with MISleep Solutions LLC in Michigan further demonstrates progress in their updated sleep practice management model [2].

Investors are encouraged to participate in the conference call to gain insights into Vivos' Q2 2025 financial performance and recent milestones. For more information, visit Vivos' investor relations website.

References:
[1] https://www.biospace.com/press-releases/vivos-therapeutics-schedules-release-of-second-quarter-2025-financial-results-and-conference-call
[2] https://www.stocktitan.net/news/VVOS/vivos-therapeutics-reports-second-quarter-2025-financial-results-and-sfvcykcvoomr.html